
Repligen Corporation
RGENNASDAQHealthcareMedical - Instruments & Supplies
Previous close
$181.13
+$0.84 · +0.47%
RGEN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
16
Overpriced
Momentum
47
Neutral
Sentiment
67
Bullish
Risk resilience
54
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteRepligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Olivier Loeillot
- Listed since
- Apr 29, 1986
- Employees
- 2,000
Market position
Day range
Current $181.13
52-week range
Current $181.13
- Open
- $179.21
- Previous close
- $180.29
- Volume
- 1.1M
- 0.93× average
- Average volume
- 1.18M
- Average daily volume
- Market cap
- 10.22B USD
- Beta
- 1.01
- Market reference 1
- 50-day average
- $146.95
- +23.26% above average
- 200-day average
- $140.61
- +28.82% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 9.34B USD
- P/E (TTM)
- 244.77×
- P/B (TTM)
- 4.84×
- P/S (TTM)
- 13.02×
- EV / EBITDA
- 56.84×
- Earnings yield
- 0.53%
- Free cash flow yield
- 1.02%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 51.05%
- Operating margin
- 8.32%
- Net margin
- 5.29%
- Return on equity
- 2.32%
- Return on assets
- 1.66%
- Return on invested capital
- 1.65%
Financial health
- Debt / equity
- 0.33×
- Current ratio
- 8.37×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 738.26M USD | 634.44M USD | 632.36M USD | 801.54M USD | 670.53M USD |
| Cost of goods sold | 390.63M USD | 359.79M USD | 353.92M USD | 345.83M USD | 279.28M USD |
| Gross profit | 347.62M USD | 274.65M USD | 278.44M USD | 455.71M USD | 391.25M USD |
| Research and development | 54.18M USD | 43.2M USD | 42.72M USD | 43.94M USD | 34.27M USD |
| Selling, general, and administrative | 290.51M USD | 263.37M USD | 218.58M USD | 215.83M USD | 183.87M USD |
| Operating expenses | 288.05M USD | 309.76M USD | 230.74M USD | 231.04M USD | 224.01M USD |
| Interest income | 27.57M USD | — | — | 6.98M USD | 176K USD |
| Interest expense | 23.17M USD | 22.57M USD | 10.03M USD | 2.98M USD | 12.71M USD |
| Depreciation and amortization | 78.75M USD | 86.56M USD | 86.11M USD | 57.01M USD | 38.45M USD |
| Operating income | 59.58M USD | −35.11M USD | 47.7M USD | 224.67M USD | 167.25M USD |
| Net income | 48.89M USD | −25.51M USD | 35.6M USD | 185.96M USD | 128.29M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 64%
- 7 beats, 3 misses, 1 met estimate
- Average EPS surprise
- +9.19%
- 11 comparable reports
- Latest EPS result
- 0.54
- Estimate 0.45 · Beat by 20.81%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$152
16.08% downsideRating distribution
24 ratingsRGEN news
RGEN peers
ETFs holding RGEN
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Mid-Cap ETFIJH310.04M0.24%125.92B USD0.05%$76.77+0.52%
Vanguard Morningstar Total Stock Market ETFVTI240.91M0.01%2.3T USD0.03%$378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB173.71M0.09%183.4B USD0.03%$304.76+0.64%
First Trust NYSE Arca Biotechnology Index FundFBT112.65M3.87%2.94B USD0.55%$271.07+1.10%
Vanguard Morningstar Small-Cap Growth ETFVBK100.61M0.23%43.8B USD0.05%$358.65+0.70%
Vanguard Extended Market ETFVXF86.08M0.09%93.7B USD0.05%$245.53+0.82%
iShares Biotechnology ETFIBB71.91M0.68%10.75B USD0.44%$213.56+1.29%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY70.01M0.26%26.72B USD0.23%$699.6+0.48%
iShares Core S&P Mid-Cap ETFIJH- Market value
- 310.04M
- Weight
- 0.24%
- AUM
- 125.92B USD
- Expense ratio
- 0.05%
- Price / 1D
- $76.77+0.52%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 240.91M
- Weight
- 0.01%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 173.71M
- Weight
- 0.09%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
First Trust NYSE Arca Biotechnology Index FundFBT- Market value
- 112.65M
- Weight
- 3.87%
- AUM
- 2.94B USD
- Expense ratio
- 0.55%
- Price / 1D
- $271.07+1.10%
Vanguard Morningstar Small-Cap Growth ETFVBK- Market value
- 100.61M
- Weight
- 0.23%
- AUM
- 43.8B USD
- Expense ratio
- 0.05%
- Price / 1D
- $358.65+0.70%
Vanguard Extended Market ETFVXF- Market value
- 86.08M
- Weight
- 0.09%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Biotechnology ETFIBB- Market value
- 71.91M
- Weight
- 0.68%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY- Market value
- 70.01M
- Weight
- 0.26%
- AUM
- 26.72B USD
- Expense ratio
- 0.23%
- Price / 1D
- $699.6+0.48%
Continue in GoAI
Research RGENresearch.disclaimer











